Skip to main content
All lobbying filings

TERUMO BCT, INC.

Lobbying for TERUMO BCT, INC. · Medical technology company

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$20,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Colorado

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 3
Health Issues

S.721/H.R. 5178 - Sickle Cell Disease Comprehensive Care Act Blood and cell collection, storage, and processing Blood donation supply and quality

Medicare/Medicaid

Medicaid Eligibility, work and community engagement requirements

Trade (domestic/foreign)

Global trade and tariffs

 Bills named in this filing 2
  • S. 721
    Sickle Cell Disease Comprehensive Care Act
  • H.R. 5178
    Sickle Cell Disease Comprehensive Care Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem